M
Michel Moutschen
Researcher at University of Liège
Publications - 200
Citations - 5294
Michel Moutschen is an academic researcher from University of Liège. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 33, co-authored 174 publications receiving 4256 citations. Previous affiliations of Michel Moutschen include Institute of Tropical Medicine Antwerp.
Papers
More filters
Journal ArticleDOI
Deleterious Mutations in LRBA Are Associated with a Syndrome of Immune Deficiency and Autoimmunity
G Lopez-Herrera,Giacomo Tampella,Qiang Pan-Hammarström,Peer Herholz,Claudia M. Trujillo-Vargas,Claudia M. Trujillo-Vargas,Kanchan Phadwal,Anna Katharina Simon,Anna Katharina Simon,Michel Moutschen,Amos Etzioni,Adi Mory,Izhak Srugo,Doron Melamed,Kjell Hultenby,Chonghai Liu,Chonghai Liu,Manuela Baronio,Massimiliano Vitali,Pierre Philippet,Vinciane Dideberg,Asghar Aghamohammadi,Nima Rezaei,Victoria Enright,Likun Du,Ulrich Salzer,Hermann Eibel,Dietmar Pfeifer,Hendrik Veelken,Hans J. Stauss,Vassilios Lougaris,Alessandro Plebani,E. Michael Gertz,Alejandro A. Schäffer,Lennart Hammarström,Bodo Grimbacher +35 more
TL;DR: It is concluded that mutations in LRBA cause an immune deficiency characterized by defects in B cell activation and autophagy and by susceptibility to apoptosis, all of which are associated with a clinical phenotype of hypogammaglobulinemia and autoimmunity.
Journal ArticleDOI
Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double- Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein- Barr Virus Vaccine in Healthy Young Adults
Etienne Sokal,Karel Hoppenbrouwers,Corinne Vandermeulen,Michel Moutschen,Philippe Leonard,Andre Moreels,Michèle Haumont,Alex Bollen,Françoise Smets,Martine Denis +9 more
TL;DR: These data support the clinical feasibility of using an EBV vaccine to prevent infectious mononucleosis and there were no concerns regarding the safety or reactogenicity of the gp350/AS04 vaccine.
Journal ArticleDOI
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
Charlotte Schwab,Annemarie Gabrysch,Peter Olbrich,Virginia Patiño,Klaus Warnatz,Daniel Wolff,Akihiro Hoshino,Masao Kobayashi,Kohsuke Imai,Masatoshi Takagi,Ingunn Dybedal,Jamanda A. Haddock,David M. Sansom,José Manuel Lucena,Maximilian Seidl,Annette Schmitt-Graeff,Veronika Reiser,Florian Emmerich,Natalie Frede,Alla Bulashevska,Ulrich Salzer,Desirée Schubert,Seiichi Hayakawa,Satoshi Okada,Maria Kanariou,Zeynep Yesim Kucuk,Hugo Chapdelaine,Lenka Petruzelkova,Zdenek Sumnik,Anna Sediva,Mary Slatter,Peter D. Arkwright,Andrew J. Cant,Hanns-Martin Lorenz,Thomas Giese,Vassilios Lougaris,Alessandro Plebani,Christina Price,Kathleen E. Sullivan,Michel Moutschen,Jiri Litzman,Tomáš Freiberger,Frank L. van de Veerdonk,Mike Recher,Michael H. Albert,Fabian Hauck,Suranjith L. Seneviratne,Jana Pachlopnik Schmid,Antonios G.A. Kolios,Gary Unglik,Christian Klemann,Christian Klemann,Carsten Speckmann,Stephan Ehl,Alan M. Leichtner,Richard S. Blumberg,Andre Franke,Scott B. Snapper,Sebastian Zeissig,Sebastian Zeissig,Sebastian Zeissig,Charlotte Cunningham-Rundles,Lisa Giulino-Roth,Olivier Elemento,Gregor Dückers,Tim Niehues,Eva Fronkova,Veronika Kanderova,Craig D. Platt,Janet Chou,Talal A. Chatila,Raif S. Geha,Elizabeth M. McDermott,Su Bunn,Monika Kurzai,Ansgar Schulz,Laia Alsina,Ferran Casals,Angela Deyà-Martínez,Sophie Hambleton,Hirokazu Kanegane,Kjetil Taskén,Olaf Neth,Bodo Grimbacher,Bodo Grimbacher +84 more
TL;DR: The penetrance, clinical features, laboratory values, and outcomes of treatment options were assessed in a worldwide cohort of CTLA4 mutation carriers, finding affected mutation carriers with CTLA‐4 insufficiency can present in any medical specialty.
Journal ArticleDOI
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
Fabrizio De Benedetti,Marco Gattorno,Jordi Anton,Eldad Ben-Chetrit,Joost Frenkel,Hal M. Hoffman,Isabelle Koné-Paut,Helen J. Lachmann,Seza Ozen,Anna Simon,Andrew Zeft,Inmaculada Calvo Penades,Michel Moutschen,Pierre Quartier,Ozgur Kasapcopur,Anna Shcherbina,Michael Hofer,Philip J. Hashkes,Jeroen Van der Hilst,Ryoki Hara,Segundo Bujan-Rivas,Tamás Constantin,Ahmet Gül,Avi Livneh,Paul A. Brogan,Marco Cattalini,Laura Obici,Karine Lheritier,A. Speziale,Guido Junge +29 more
TL;DR: In this trial, canakinumab was effective in controlling and preventing flares in patients with colchicine‐resistant familial Mediterranean fever, mevalonate kinase deficiency, and TRAPS.
Journal Article
Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections.
TL;DR: In this article, a review analyzes some of these models and their clinical relevance and suggests the involvement of insulinopenia in some of the abnormalities observed, and several mechanisms have been proposed to link the different defects observed with specific infections encountered in diabetic patients.